Article Abstract

Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer

Authors: Daniel J. Crona, Young E. Whang


For over 70 years, androgen deprivation therapy (ADT) has been a fundamental treatment paradigm for advanced prostate cancer. Despite initial effectiveness, castration resistant prostate cancer (CRPC) develops in virtually all patients while on ADT. Until recently, additional available treatment options were limited for CPRC patients. Recognition of the critical role of reactivated androgen receptor (AR) signaling in CRPC led to the development of two novel AR axis-targeting agents, abiraterone and enzalutamide.


  • There are currently no refbacks.

Article Options

Download Citation